We took into consideration age; gender; APOE polymorphisms; LDLR, LRP1, and LRPAP1 SNPs; smoking history; and statin usage in our initial model (Model I) because they are suspected to influence both circulating cholesterol levels and the occurrence of PD. This evidence concerns the gene APOE and Parkinson disease.